Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety

Phio Pharmaceuticals Corp.

Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.
R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.
G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.
PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.
ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Phio Pharmaceuticals Corp. reported quarter ended March 31, 2026 results: net income $4.0 million.

Period: quarter ended March 31, 2026
Net income: $4.0 million
Result: reported results

Exact text from the filing

31, 2025. The increase in general and administrative expenses was primarily driven by employee related costs, investor outreach and professional fees. Net Loss Net loss was $ 4.0 million for the three months ended March 31, 2026 as compared with $1.8 million for the three months ended March 31, 2025. The increase in net loss was attributable to increases in

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001437749-26-015590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.